(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Clinical trial NCT04862780 · TERMINATED

Trial details

NCT number: NCT04862780
Sponsor: Blueprint Medicines Corporation
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Disease Carcinoma, Bronchogenic Bronchial Neoplasms Adenocarcinoma Carcinoma Neoplasms by Histologic Type

Start date: 2021-06-29
Primary completion: 2024-10-07
Enrollment: 177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.